| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198753 | 2013-12-20 | ||
| EP14158331 | 2014-03-07 | ||
| PCT/EP2014/078233WO2015091655A1 (en) | 2013-12-20 | 2014-12-17 | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
| Publication Number | Publication Date |
|---|---|
| SG11201604594SAtrue SG11201604594SA (en) | 2016-07-28 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201604594SASG11201604594SA (en) | 2013-12-20 | 2014-12-17 | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
| Country | Link |
|---|---|
| US (3) | US20150232548A1 (en) |
| EP (1) | EP3082857B1 (en) |
| JP (1) | JP6345787B2 (en) |
| KR (1) | KR20160085888A (en) |
| CN (1) | CN105611944A (en) |
| AU (1) | AU2014368695A1 (en) |
| BR (1) | BR112016007112A2 (en) |
| CA (1) | CA2923591A1 (en) |
| CL (1) | CL2016001586A1 (en) |
| CR (1) | CR20160199A (en) |
| EA (1) | EA201600474A1 (en) |
| HK (1) | HK1221409A1 (en) |
| IL (1) | IL244454A0 (en) |
| MX (1) | MX2016008099A (en) |
| PE (1) | PE20160753A1 (en) |
| PH (1) | PH12016500482A1 (en) |
| SG (1) | SG11201604594SA (en) |
| TW (1) | TWI559931B (en) |
| WO (1) | WO2015091655A1 (en) |
| ZA (1) | ZA201601895B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658924B2 (en)* | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| SG11201701070WA (en) | 2014-08-12 | 2017-03-30 | Alligator Bioscience Ab | Combination therapies with anti cd40 antibodies |
| JP2017534644A (en)* | 2014-11-10 | 2017-11-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Anti-ANG2 antibody and method of use |
| CN107074941A (en) | 2014-11-10 | 2017-08-18 | 豪夫迈·罗氏有限公司 | Bispecific antibody and for ophthalmologic method |
| AU2015345320A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-IL-1beta antibodies and methods of use |
| JP7350467B2 (en) | 2015-06-29 | 2023-09-26 | ブリストル－マイヤーズ スクイブ カンパニー | Antibodies against CD40 |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| JP2019521988A (en)* | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | EZH2 inhibitor for treating cancer |
| AR113862A1 (en)* | 2017-12-01 | 2020-06-17 | Seattle Genetics Inc | ANTI-CD47 ANTIBODIES AND THEIR USES TO TREAT CANCER |
| US11306149B2 (en) | 2017-12-27 | 2022-04-19 | Bristol-Myers Squibb Company | Anti-CD40 antibodies and uses thereof |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| MA52889A (en) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V Inc | INCREASED IMMUNE ACTIVITY BY MODULATION OF POST-CELLULAR SIGNALING FACTORS |
| PH12021500024A1 (en)* | 2018-10-01 | 2022-05-02 | Hoffmann La Roche | Bispecific antigen binding molecules comprising anti-fap clone 212 |
| CA3131250A1 (en)* | 2019-02-25 | 2020-09-03 | Pharmabcine Inc. | Anti-ang2 antibody and use thereof |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| MA56394A (en) | 2019-06-27 | 2022-05-04 | Boehringer Ingelheim Int | ANTI-ANGPT2 ANTIBODIES |
| CN112168960A (en)* | 2019-07-03 | 2021-01-05 | 义慧科技(深圳)有限公司 | Use of anti-VEGF antibody and anti-ANG2 antibody for the preparation of a medicament for the treatment of tumors with Ras mutations |
| US20220370418A1 (en) | 2019-09-09 | 2022-11-24 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
| AR124414A1 (en) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | CHIMERIC ANTIGEN RECEPTOR SYSTEM WITH ADAPTABLE RECEPTOR SPECIFICITY |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039067A1 (en)* | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
| US8268314B2 (en)* | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en)* | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| TWI426920B (en)* | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | Bispecific, bivalent anti-VEGF/anti-ANG-2 antibody |
| AR090263A1 (en)* | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | COMBINED ANTIBODY THERAPY AGAINST HUMAN CSF-1R AND USES OF THE SAME |
| Publication number | Publication date |
|---|---|
| WO2015091655A1 (en) | 2015-06-25 |
| TW201526915A (en) | 2015-07-16 |
| KR20160085888A (en) | 2016-07-18 |
| BR112016007112A2 (en) | 2017-09-19 |
| TWI559931B (en) | 2016-12-01 |
| PH12016500482A1 (en) | 2016-05-16 |
| IL244454A0 (en) | 2016-04-21 |
| CL2016001586A1 (en) | 2017-05-12 |
| EP3082857A1 (en) | 2016-10-26 |
| HK1221409A1 (en) | 2017-06-02 |
| ZA201601895B (en) | 2018-11-28 |
| US20150232548A1 (en) | 2015-08-20 |
| JP6345787B2 (en) | 2018-06-20 |
| CR20160199A (en) | 2016-06-17 |
| EP3082857B1 (en) | 2018-07-25 |
| PE20160753A1 (en) | 2016-08-01 |
| US20200199215A1 (en) | 2020-06-25 |
| MX2016008099A (en) | 2016-10-13 |
| CN105611944A (en) | 2016-05-25 |
| JP2017504600A (en) | 2017-02-09 |
| AU2014368695A1 (en) | 2016-04-14 |
| EA201600474A1 (en) | 2016-11-30 |
| CA2923591A1 (en) | 2015-06-25 |
| US20180134780A1 (en) | 2018-05-17 |
| Publication | Publication Date | Title |
|---|---|---|
| TWI559931B (en) | Combination therapy with an anti-ang2 antibody and a cd40 agonist | |
| IL276113B (en) | E-vaping section and e-vaping device | |
| IL263026A (en) | Ibrutinib combination therapy | |
| ZA201504902B (en) | Bcl-2bcl-xl inhibitors and therapeutic methods using the same | |
| HK1214972A1 (en) | Supplemental device for use with an injection device | |
| EP3081627A4 (en) | Well plate and subject selection device provided with well plate | |
| SG10201708409VA (en) | Medicament device | |
| EP2992870A4 (en) | Coinjection device and coinjection method | |
| EP3145565A4 (en) | Combined laryngo-tracheal anesthetic and stylet device | |
| PL3054856T3 (en) | Device for synchronized injection and aspiration | |
| EP3010577A4 (en) | Radioactive therapeutic device with fixation | |
| GB201317955D0 (en) | Metering device and parts therefor | |
| HK1224233A1 (en) | Syringe and syringe set | |
| HUE044705T2 (en) | Furniture fitting with securing device | |
| IL242785B (en) | Device for signature adaptation and object provided with device for signature adaptation | |
| EP2979200A4 (en) | Query features and questions | |
| EP3088024A4 (en) | Drug injection device | |
| HK1217170A1 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine l-4- | |
| EP3027264A4 (en) | Nanochanneled device with electrodes and related methods | |
| HK1223266A1 (en) | Drug supply unit and drug supply device | |
| EP2997998A4 (en) | Therapy device for edema and neuropathy | |
| GB201311107D0 (en) | Bioorthogonal methods and compounds | |
| GB201312600D0 (en) | Needle assemblies and methods | |
| GB201300141D0 (en) | An infusion device | |
| GB201317956D0 (en) | Metering device and parts therefor |